Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial.

ABSTRACT:

Background

Pre-treatment factors that increase smokers' risk of experiencing neuropsychiatric adverse events (NPSAEs) when quitting smoking are unknown.

Objective

To identify baseline smoker characteristics beyond the history of mental illness that predict which participants were more likely to experience moderate to severe NPSAEs in EAGLES.

Design

A prospective correlational cohort study in the context of a multinational, multicenter, double-blind, randomized trial.

Participants

Smokers without (N = 3984; NPC)/with (N = 4050; PC) histories of, or current clinically stable, psychiatric disorders including mood (N = 2882; 71%), anxiety (N = 782; 19%), and psychotic (N = 386; 10%) disorders.

Interventions

Bupropion, 150 mg twice daily, or varenicline, 1 mg

SUBMITTER: Anthenelli RM 

PROVIDER: S-EPMC6544691 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature